Clinical Trials Directory

Trials / Unknown

UnknownNCT00418743

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy.

Status
Unknown
Phase
Study type
Observational
Enrollment
138 (estimated)
Sponsor
Groupe Francais De Pneumo-Cancerologie · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Detailed description

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Conditions

Timeline

Start date
2005-12-01
Completion
2010-05-01
First posted
2007-01-05
Last updated
2010-03-09

Locations

24 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00418743. Inclusion in this directory is not an endorsement.

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC) (NCT00418743) · Clinical Trials Directory